• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纳武利尤单抗诱导的大疱性类天疱疮成功用度普利尤单抗治疗。

A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab.

机构信息

Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.

出版信息

Dermatol Online J. 2022 Mar 15;28(2). doi: 10.5070/D328257396.

DOI:10.5070/D328257396
PMID:35670683
Abstract

A 76-year-old man came to our attention for the presence of itchy skin lesions localized on the trunk. The patient had a nodular melanoma removed two years earlier. Because of metastatic pulmonary melanoma, he underwent a lung lobectomy and began adjuvant therapy with nivolumab. After six months of treatment, the patient reported the appearance of itchy lesions on the trunk that were diagnosed as eczema and successfully treated with systemic corticosteroids. Upon corticosteroid discontinuation, the eruption relapsed presenting with erythematous macules, tense blisters, and erosions on the trunk and limbs. The presence of linear deposits of IgG and C3 at the dermo-epidermal junction and high serum levels of anti-BP180 antibodies confirmed the suspicion of nivolumab-induced bullous pemphigoid. Treatment with 0.6mg/kg methylprednisolone and 200mg/day doxycycline as well as nivolumab discontinuation induced temporary remission. After tapering methylprednisolone to 16mg/day, the patient developed new blisters. Therefore, dupilumab 300mg every other week was added with progressive improvement while methylprednisolone was tapered down and withdrawn after four months. After six months the patient was still in full clinical remission. Many cases of conventional bullous pemphigoid have been treated successfully with dupilumab, which can also be used safely in cancer patients without inducing overt immunosuppression.

摘要

一位 76 岁男性因躯干部位出现瘙痒性皮肤病变而就诊。该患者两年前曾因结节性黑色素瘤而接受手术切除。由于患有转移性肺黑色素瘤,他接受了肺叶切除术,并开始接受纳武利尤单抗辅助治疗。治疗六个月后,患者报告躯干出现瘙痒性病变,被诊断为湿疹,并成功接受全身皮质类固醇治疗。皮质类固醇停药后,皮损复发,表现为躯干和四肢的红斑性斑丘疹、紧张性水疱和糜烂。真皮表皮交界处 IgG 和 C3 的线性沉积以及抗 BP180 抗体的血清水平升高证实了纳武利尤单抗诱导性大疱性类天疱疮的怀疑。使用 0.6mg/kg 甲基强的松龙和 200mg/天多西环素以及纳武利尤单抗停药诱导暂时缓解。在将甲基强的松龙逐渐减少至 16mg/天后,患者出现新的水疱。因此,每隔一周给予 300mg 度普利尤单抗,并逐渐减少甲基强的松龙的剂量,四个月后停用。四个月后,患者仍处于完全临床缓解状态。许多常规大疱性类天疱疮病例已成功用度普利尤单抗治疗,并且在癌症患者中也可以安全使用,而不会引起明显的免疫抑制。

相似文献

1
A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab.纳武利尤单抗诱导的大疱性类天疱疮成功用度普利尤单抗治疗。
Dermatol Online J. 2022 Mar 15;28(2). doi: 10.5070/D328257396.
2
Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.度普利尤单抗治疗中重度大疱性类天疱疮的疗效和安全性。
Front Immunol. 2021 Oct 14;12:738907. doi: 10.3389/fimmu.2021.738907. eCollection 2021.
3
Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid.尼伏鲁单抗诱导性大疱性类天疱疮的临床特征、治疗和转归。
Invest New Drugs. 2023 Dec;41(6):802-807. doi: 10.1007/s10637-023-01397-w. Epub 2023 Sep 29.
4
Development of bullous pemphigoid following radiation therapy combined with nivolumab for renal cell carcinoma: A case report of abscopal toxicities.放射性治疗联合纳武利尤单抗治疗肾细胞癌后出现大疱性类天疱疮:一种远隔毒性的病例报告。
Medicine (Baltimore). 2021 Dec 10;100(49):e28199. doi: 10.1097/MD.0000000000028199.
5
Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.度普利尤单抗治疗纳武利尤单抗诱导的大疱性类天疱疮:一例病例报告及文献综述
Dermatol Online J. 2021 Sep 15;27(9). doi: 10.5070/D327955136.
6
Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.转移性肾细胞癌患者停用免疫检查点抑制剂后疾病持久控制且并发难治性大疱性类天疱疮:一例报告。
Front Immunol. 2022 Sep 16;13:984132. doi: 10.3389/fimmu.2022.984132. eCollection 2022.
7
Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature.大疱性类天疱疮样皮肤病变和明显嗜酸性粒细胞增多症在接受纳武利尤单抗治疗的黑色素瘤患者中:病例报告及文献复习。
J Immunother. 2018 Apr;41(3):164-167. doi: 10.1097/CJI.0000000000000210.
8
Nivolumab-induced localized genital bullous pemphigoid in a 60-year-old male.纳武利尤单抗诱导 60 岁男性局限性生殖器大疱性类天疱疮。
J Cutan Pathol. 2022 May;49(5):468-471. doi: 10.1111/cup.14183. Epub 2022 Jan 12.
9
Bullous Pemphigoid Masquerading as Erythema Annulare Centrifugum.伪装成离心性环状红斑的大疱性类天疱疮
Acta Dermatovenerol Croat. 2017 Oct;25(3):255-256.
10
Concomitant nivolumab-associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma.一名转移性肾细胞癌患者并发纳武利尤单抗相关的格罗弗病和大疱性类天疱疮。
J Cutan Pathol. 2023 Jun;50(6):520-523. doi: 10.1111/cup.14383. Epub 2023 Jan 24.

引用本文的文献

1
Dupilumab for the Treatment of Cutaneous Immune-Related Adverse Events: A Systematic Review.度普利尤单抗治疗皮肤免疫相关不良事件的系统评价
Int J Dermatol. 2025 Oct;64(10):1825-1832. doi: 10.1111/ijd.17850. Epub 2025 May 15.
2
Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events.接受度普利尤单抗治疗皮肤免疫相关不良事件的免疫治疗患者的长期死亡率结局。
J Immunother Cancer. 2025 May 12;13(5):e010638. doi: 10.1136/jitc-2024-010638.
3
Omalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Review.
奥马珠单抗和度普利尤单抗治疗大疱性类天疱疮:一项系统评价
J Clin Med. 2024 Aug 16;13(16):4844. doi: 10.3390/jcm13164844.
4
Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update.大疱性类天疱疮治疗的进展:全面的药物研发管线更新。
Am J Clin Dermatol. 2024 Mar;25(2):195-212. doi: 10.1007/s40257-023-00832-1. Epub 2023 Dec 29.
5
Potential Indications of Dupilumab in Th-2 Inflammatory Disease.度普利尤单抗在 Th2 炎症性疾病中的潜在适应证。
Rev Recent Clin Trials. 2024;19(1):53-61. doi: 10.2174/0115748871263396231121060901.
6
Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab.纳武单抗继发大疱性类天疱疮的延迟发作
Cureus. 2023 Aug 9;15(8):e43230. doi: 10.7759/cureus.43230. eCollection 2023 Aug.
7
Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: A case series and review of the literature.度普利尤单抗治疗免疫检查点抑制剂引起的皮肤免疫相关不良事件:病例系列及文献综述
SAGE Open Med Case Rep. 2023 Aug 25;11:2050313X231195462. doi: 10.1177/2050313X231195462. eCollection 2023.
8
Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience.接受免疫治疗的癌症患者中的自身免疫性大疱性皮肤病:文献综述及意大利多中心经验
Front Med (Lausanne). 2023 Jul 20;10:1208418. doi: 10.3389/fmed.2023.1208418. eCollection 2023.
9
Anti-interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study.抗白细胞介素 4 受体 α 抗体治疗伴有多种合并症的中国大疱性类天疱疮患者:一项单中心真实世界研究。
Front Immunol. 2023 Jul 20;14:1165106. doi: 10.3389/fimmu.2023.1165106. eCollection 2023.
10
Dupilumab in Inflammatory Skin Diseases: A Systematic Review.度普利尤单抗治疗炎症性皮肤病:系统评价。
Biomolecules. 2023 Mar 31;13(4):634. doi: 10.3390/biom13040634.